HealthTree Logo
search more_vert
close
person Sign In / Create Account
The Open IMMUNOPET Clinical Trial (for NonSecretors!)
The Open IMMUNOPET Clinical Trial (for NonSecretors!) image
Non-Secretory Myeloma Community
event Oct 20, 2022 / 01:00PM - 02:00PM EDT

Event Description

Nonsecretory myeloma patients are often excluded from clinical trial participation. But one of the brightest minds in myeloma, Dr. Ola Landgren, has created a clinical trial in which a novel immunoPET tracer was designed to detect CD38 (a common myeloma marker present in even nonsecretory patients) in a PET scanner.

This allows a full visualization of myeloma within the entire body and can change how we measure disease burden in myeloma patients!

Join us to learn from a bright mind and perhaps register yourself for this exciting and innovative clinical trial. This is a once in a lifetime opportunity!

Schedule & Agenda

The panelist Audrey Burton-Bethke
Introductions
01:00PM
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Ola Landgren.

The panelist C. Ola Landgren, MD, PhD
Presentation/Interview
01:05PM
C. Ola Landgren, MD, PhD

Dr. Ola Landgren talks about the new clinical trial in which a novel immunoPET tracer was designed to detect CD38 (a common myeloma marker present in even nonsecretory patients) in a PET scanner.

person
Questions and Answers
01:35PM
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist C. Ola Landgren, MD, PhD
C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Read Bio
The panelist Vicki Jones
Vicki Jones

Vicki has been fighting Myeloma since 2004 when she was diagnosed with stage 2 Myeloma and began aggressive chemotherapy. After a stem cell transplant in 2007 from which she obtained a very good partial response, Vicki has been on just about every drug regimen available. Every drug has worked well but, of course, nothing works forever. Recently after being IGA lambda for over 17 years, Vicki became a non-secretor and now leads Healthtree’s non secretory community group. Throughout her myeloma journey, Vicki has gratefully maintained an excellent quality of life and now finds joy in helping others diagnosed with Myeloma.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Regeneron
Adaptive
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube